This article is more than 5 years old. Information may no longer be current.

Artificial pancreas meets real-world goals for effective diabetes management

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Real-world data from 120,000 individuals with diabetes revealed that those using a hybrid closed-loop insulin delivery system maintained blood glucose within a range of 70 mg/dL to 180 mg/dL for 71% of the time, according to a press release from Medtronic.

The MiniMed 670G consists of a continuous glucose monitor that measures glucose levels every 5 minutes and an insulin pump and infusion patch to deliver basal insulin in response to glucose levels based on an algorithm, referred to as “automode.” With the automode feature, users experienced an average of 2.3 hours more per day in range vs. those not using the feature, based on findings across 8 million patient days, according to the release.

According to Robert Vigersky, MD, chief medical officer for the Diabetes Group at Medtronic, staying within a range between 70 mg/dL and 180 mg/dL for 70% of the day is “the goal of effective diabetes management.”

Additional benefits of this hybrid closed-loop system were a 28% reduction in times where sensor glucose dropped below 70 mg/dL for at least 20 minutes and a 55% reduction in times levels rose above 250 mg/dL for more than 3 hours, the company stated.

“For people with type 1 diabetes, it means a lot,” Satish Garg, MD, professor of medicine and pediatrics and director of the adult diabetes division of the Barbara Davis Center of the University of Colorado, told Endocrine Today. “Many people just give up the system partly because it kicks them out, it keeps asking for repeated calibrations, and, in all fairness to Medtronic, this was the first system that was ever approved. This is a step in the right direction, but new future systems will only improve the technology.” by Phil Neuffer

For more information:

Satish Garg, MD, can be reached at satish.garg@ucdenver.edu.

Disclosures: Garg reports he has served on advisory boards for Dexcom, Eli Lilly, Lexicon, Mannkind, Medtronic, Merck, Roche and Sanofi, and received research grants through his institution from Animas, Dario, Dexcom, Eli Lilly, JDRF, Lexicon, Medtronic, Merck, NIDDK, Novo Nordisk, Sanofi and T1D Exchange.